Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

被引：2
|
作者：
Yu, Wen-Jing [1 ]
Wu, Ying [1 ]
Chen, Qi [1 ]
Zhu, Xiaolu [1 ]
Pei, Xu-Ying [1 ]
Jia, Jin-Song [2 ]
Wang, Jing [1 ]
Zhao, Xiao-Su [1 ]
Chang, Ying-Jun [1 ]
Lai, Yue-Yun [1 ]
Shi, Hong-Xia [1 ]
Ruan, Guo-Rui [1 ]
Qin, Ya-Zhen [1 ]
Liu, Xiao-Hong [1 ]
Huang, Xiao Jun [1 ,3 ]
Jiang, Hao [1 ]
机构：
[1] Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol, Natl Clin Res Ctr Hematol Dis,Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ, Inst Hematol, Peoples Hosp, Beijing, Peoples R China
[3] Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184665
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Wei, Guoqing
    Ni, Wanmao
    Chiao, Jen-wei
    Cai, Zhen
    Huang, He
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [2] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Guoqing Wei
    Wanmao Ni
    Jen-wei Chiao
    Zhen Cai
    He Huang
    Delong Liu
    Journal of Hematology & Oncology, 4
  • [3] Meta-Analysis of CAG (cytarabine, aclarubicin, G-CSF) Regimen for the Treatment of 580 Patients with Acute Leukemia In China and Japan
    Wei, Guoqing
    Liu, Delong
    BLOOD, 2010, 116 (21) : 465 - 466
  • [4] A Meta-Analysis of CAG (cytarabine, aclarubicin, G-CSF) Regimen for the Treatment of 1045 Patients with Leukemia in China and Japan
    Wei, Guoqing
    Ni, Wanmao
    Chiao, Dicky
    Huang, He
    Cai, Zhen
    Liu, Delong
    BLOOD, 2011, 118 (21) : 1554 - 1554
  • [5] CYTARABINE, ACLARUBICIN IN COMBINATION WITH G-CSF (CAG) REGIMEN REPRESENTS AN ALTERNATIVE RE-INDUCTION OPTION FOR NON-REMISSION ACUTE MYELOID LEUKEMIA
    Lei, Meiqing
    Liu, Limin
    Wu, Depei
    ACTA MEDICA MEDITERRANEA, 2019, 35 (05): : 2561 - 2566
  • [6] Efficacy and safety evaluation of Venetoclax combined with homoharringtonine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia
    Wei, Mingxia
    Shen, Xuliang
    Zhai, Chunyan
    Gao, Wenyu
    PANMINERVA MEDICA, 2024,
  • [7] D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation
    Zheng, Runhui
    Xie, Bailu
    Wang, Chunyan
    Yu, Baodan
    Xu, Jun
    Tan, Huo
    ANNALS OF HEMATOLOGY, 2016, 95 (01) : 157 - 159
  • [8] D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation
    Runhui Zheng
    Bailu Xie
    Chunyan Wang
    Baodan Yu
    Jun Xu
    Huo Tan
    Annals of Hematology, 2016, 95 : 157 - 159
  • [9] Aclarubicin, Low-Dose Cytarabine Combined With G-CSF (CAG) Regimen For Patients Previously Treated Or Ineligible For Intensive Chemotherapy With Acute Myeloid Leukemia and Myelodysplastic Syndrom: A Single Center Experience
    Minauchi, Koichiro
    Obara, Masato
    Ara, Takahide
    Shima, Kanako
    Yasumoto, Atsushi
    Nakata, Masanobu
    Ota, Shuichi
    Imai, Kiyotoshi
    Hirano, Teiichi
    Kiyama, Yoshio
    Ogasawara, Masahiro
    Kobayashi, Naoki
    Imamura, Masahiro
    BLOOD, 2013, 122 (21)
  • [10] Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy
    Chen, Yili
    Dai, Min
    Liu, Qifa
    BLOOD, 2019, 134
12345